Related references
Note: Only part of the references are listed.Retinoic acid induced repair in the lung of adult hyperoxic mice, reducing transforming growth factor-beta 1 (TGF-beta 1) mediated abnormal alterations
Ozgecan Kayalar et al.
ACTA HISTOCHEMICA (2014)
The Copper Chelator Tetrathiomolybdate Regressed Bleomycin-Induced Pulmonary Fibrosis in Mice, by Reducing Lysyl Oxidase Expressions
Hale Ovet et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Therapeutic Targeting of Src Kinase in Myofibroblast Differentiation and Pulmonary Fibrosis
Meng Hu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Atorvastatin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Suppressing iNOS Expression and the CTGF (CCN2)/ERK Signaling Pathway
Bo Zhu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts
Johanna Donovan et al.
FIBROGENESIS & TISSUE REPAIR (2013)
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
Sabina A. Antoniu
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2012)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero et al.
CLINICAL CANCER RESEARCH (2011)
Myofibroblast differentiation and survival in fibrotic disease
Kornelia Kis et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Integrating mechanisms of pulmonary fibrosis
Thomas A. Wynn
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
MEK inhibition suppresses the development of lung fibrosis in the bleomycin model
Maria Galuppo et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pulmonary toxicities from targeted therapies: a review
Nicholas A. Barber et al.
TARGETED ONCOLOGY (2011)
Imatinib Treatment for Idiopathic Pulmonary Fibrosis Randomized Placebo-controlled Trial Results
Craig E. Daniels et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF)
Katerina M. Antoniou et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2010)
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats
Kenji Adachi et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2010)
Cathepsin B inhibition improves lung injury associated to d-galactosamine/tumor necrosis factor-alpha-induced liver injury in mice
Fusun Oztay et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts
Silke Haubeiss et al.
MOLECULAR CANCER (2010)
Mesenchymal cell survival in airway and interstitial pulmonary fibrosis
James C. Bonner
FIBROGENESIS & TISSUE REPAIR (2010)
VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice
Xue-Mei Ou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells
Audrey Sirvent et al.
BIOLOGY OF THE CELL (2008)
Standardized quantification of pulmonary fibrosis in histological samples
Ralf-Harto Huebner et al.
BIOTECHNIQUES (2008)
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
Alfiya Akhmetshina et al.
FASEB JOURNAL (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGF beta 1, IL-13 and CCL2
Lynne A. Murray et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Cellular and molecular mechanisms of fibrosis
T. A. Wynn
JOURNAL OF PATHOLOGY (2008)
Role of PDGF in fibrotic diseases and systemic sclerosis
M. Trojanowska
RHEUMATOLOGY (2008)
Role of α1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice
Momoyo Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
N. I. Chaudhary et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: Implications for treatment of fibrotic diseases
Ragini Vittal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Gefitinib prevents bleomycin-induced lung fibrosis in mice
Yoshiki Ishii et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10)
ES White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta 1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro
YB Hu et al.
LUNG (2006)
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
FM Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
H Yoshiji et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2005)
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
A Abdollahi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Imatinib mesylate blocks a non-smad TGF-beta pathway and reduces renal fibrogenesis in vivo
SN Wang et al.
FASEB JOURNAL (2005)
Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury
R Vittal et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system
A Bikfalvi
BIOCHEMICAL PHARMACOLOGY (2004)
Regulation of PDGF and its receptors in fibrotic diseases
JC Bonner
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis
H Matsuoka et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2002)
PTEN controls tumor-induced angiogenesis
SH Wen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
